Tokyo Tape
Sign in
← Sapporo Clinical Laboratory

Annual report

9776.TEDINET S100TWXM
Period2023-04-01 → 2024-03-31
Filed2024-06-27
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 148
MetricValuePeriodScopeSource row
Revenue¥19.7bn2023-04-01 → 2024-03-31Cons.Net sales
Revenue¥20.1bn2022-04-01 → 2023-03-31Cons.Net sales
Revenue¥19.1bn2021-04-01 → 2022-03-31dCons.Net sales (5-year summary)
Revenue¥17.5bn2020-04-01 → 2021-03-31dCons.Net sales (5-year summary)
Revenue¥17.7bn2019-04-01 → 2020-03-31dCons.Net sales (5-year summary)
Operating income¥535m2023-04-01 → 2024-03-31Cons.Operating income
Operating income¥1.0bn2022-04-01 → 2023-03-31Cons.Operating income
Ordinary income¥515m2023-04-01 → 2024-03-31Cons.Ordinary income
Ordinary income¥1.2bn2022-04-01 → 2023-03-31Cons.Ordinary income
Ordinary income¥1.6bn2021-04-01 → 2022-03-31dCons.Ordinary income loss (5-year summary)
Ordinary income¥1.2bn2020-04-01 → 2021-03-31dCons.Ordinary income loss (5-year summary)
Ordinary income¥983m2019-04-01 → 2020-03-31dCons.Ordinary income loss (5-year summary)
Profit before tax¥598m2023-04-01 → 2024-03-31Cons.Income before income taxes
Profit before tax¥960m2022-04-01 → 2023-03-31Cons.Income before income taxes
Net income (owners)¥380m2023-04-01 → 2024-03-31Cons.Profit loss attributable to owners of parent
Net income (owners)¥569m2022-04-01 → 2023-03-31Cons.Profit loss attributable to owners of parent
Net income (owners)¥1.0bn2021-04-01 → 2022-03-31dCons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥794m2020-04-01 → 2021-03-31dCons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥528m2019-04-01 → 2020-03-31dCons.Profit loss attributable to owners of parent (5-year summary)
Net income¥363m2023-04-01 → 2024-03-31Cons.Profit loss
Net income¥641m2022-04-01 → 2023-03-31Cons.Profit loss
Total assets¥16.7bnat 2024-03-31Cons.Assets
Total assets¥16.5bnat 2023-03-31Cons.Assets
Total assets¥16.1bnat 2022-03-31dCons.Total assets (5-year summary)
Total assets¥14.5bnat 2021-03-31dCons.Total assets (5-year summary)
Total assets¥11.6bnat 2020-03-31dCons.Total assets (5-year summary)
Total liabilities¥5.5bnat 2024-03-31Cons.Liabilities
Total liabilities¥5.6bnat 2023-03-31Cons.Liabilities
Net assets / equity¥11.2bnat 2024-03-31Cons.Net assets
Net assets / equity¥10.9bnat 2023-03-31Cons.Net assets
Net assets / equity¥10.3bnat 2022-03-31dCons.Net assets
Net assets / equity¥9.3bnat 2021-03-31dCons.Net assets (5-year summary)
Net assets / equity¥8.5bnat 2020-03-31dCons.Net assets (5-year summary)
Cash and deposits¥4.0bnat 2024-03-31Cons.Cash and deposits
Cash and deposits¥3.7bnat 2023-03-31Cons.Cash and deposits
Cash & equivalents¥4.0bnat 2024-03-31Cons.Cash and cash equivalents
Cash & equivalents¥3.7bnat 2023-03-31Cons.Cash and cash equivalents
Cash & equivalents¥3.0bnat 2022-03-31dCons.Cash and cash equivalents
Cash & equivalents¥2.4bnat 2021-03-31dCons.Cash and cash equivalents (5-year summary)
Cash & equivalents¥2.7bnat 2020-03-31dCons.Cash and cash equivalents (5-year summary)
Operating cash flow¥1.1bn2023-04-01 → 2024-03-31Cons.Net cash provided by used in operating activities
Operating cash flow¥1.4bn2022-04-01 → 2023-03-31Cons.Net cash provided by used in operating activities
Operating cash flow¥1.6bn2021-04-01 → 2022-03-31dCons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥838m2020-04-01 → 2021-03-31dCons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥1.3bn2019-04-01 → 2020-03-31dCons.Net cash provided by used in operating activities (5-year summary)
Investing cash flow−¥395m2023-04-01 → 2024-03-31Cons.Net cash provided by used in investment activities
Investing cash flow−¥409m2022-04-01 → 2023-03-31Cons.Net cash provided by used in investment activities
Investing cash flow−¥831m2021-04-01 → 2022-03-31dCons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥3.1bn2020-04-01 → 2021-03-31dCons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥2.9bn2019-04-01 → 2020-03-31dCons.Net cash provided by used in investing activities (5-year summary)
Financing cash flow−¥370m2023-04-01 → 2024-03-31Cons.Net cash provided by used in financing activities
Financing cash flow−¥348m2022-04-01 → 2023-03-31Cons.Net cash provided by used in financing activities
Financing cash flow−¥113m2021-04-01 → 2022-03-31dCons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow¥1.9bn2020-04-01 → 2021-03-31dCons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow−¥52m2019-04-01 → 2020-03-31dCons.Net cash provided by used in financing activities (5-year summary)
EPS (basic)¥114.142023-04-01 → 2024-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥170.532022-04-01 → 2023-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥306.162021-04-01 → 2022-03-31dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥231.852020-04-01 → 2021-03-31dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥154.32019-04-01 → 2020-03-31dCons.Basic earnings loss per share (5-year summary)
Net assets per share¥3,283.71at 2024-03-31Cons.Net assets per share (5-year summary)
Net assets per share¥3,178.25at 2023-03-31Cons.Net assets per share (5-year summary)
Net assets per share¥3,016.24at 2022-03-31dCons.Net assets per share (5-year summary)
Net assets per share¥2,708.63at 2021-03-31dCons.Net assets per share (5-year summary)
Net assets per share¥2,472.23at 2020-03-31dCons.Net assets per share (5-year summary)
Equity ratio65.6%at 2024-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio64.1%at 2023-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio62.6%at 2022-03-31dCons.Equity to asset ratio (5-year summary)
Equity ratio63.9%at 2021-03-31dCons.Equity to asset ratio (5-year summary)
Equity ratio73.3%at 2020-03-31dCons.Equity to asset ratio (5-year summary)
ROE3.5%2023-04-01 → 2024-03-31Cons.Rate of return on equity (5-year summary)
ROE5.5%2022-04-01 → 2023-03-31Cons.Rate of return on equity (5-year summary)
ROE10.8%2021-04-01 → 2022-03-31dCons.Rate of return on equity (5-year summary)
ROE9.0%2020-04-01 → 2021-03-31dCons.Rate of return on equity (5-year summary)
ROE6.4%2019-04-01 → 2020-03-31dCons.Rate of return on equity (5-year summary)
Employees871at 2024-03-31Cons.Number of employees
Employees938at 2023-03-31Cons.Number of employees
Employees871at 2022-03-31dCons.Number of employees
Employees819at 2021-03-31dCons.Number of employees
Employees820at 2020-03-31dCons.Number of employees
Revenue¥17.3bn2023-04-01 → 2024-03-31StandaloneNet sales
Revenue¥17.6bn2022-04-01 → 2023-03-31StandaloneNet sales
Revenue¥17.7bn2021-04-01 → 2022-03-31dStandaloneNet sales (5-year summary)
Revenue¥16.4bn2020-04-01 → 2021-03-31dStandaloneNet sales (5-year summary)
Revenue¥16.5bn2019-04-01 → 2020-03-31dStandaloneNet sales (5-year summary)
Operating income¥369m2023-04-01 → 2024-03-31StandaloneOperating income
Operating income¥705m2022-04-01 → 2023-03-31StandaloneOperating income
Ordinary income¥598m2023-04-01 → 2024-03-31StandaloneOrdinary income
Ordinary income¥895m2022-04-01 → 2023-03-31StandaloneOrdinary income
Ordinary income¥1.6bn2021-04-01 → 2022-03-31dStandaloneOrdinary income loss (5-year summary)
Ordinary income¥1.2bn2020-04-01 → 2021-03-31dStandaloneOrdinary income loss (5-year summary)
Ordinary income¥944m2019-04-01 → 2020-03-31dStandaloneOrdinary income loss (5-year summary)
Profit before tax¥681m2023-04-01 → 2024-03-31StandaloneIncome before income taxes
Profit before tax¥696m2022-04-01 → 2023-03-31StandaloneIncome before income taxes
Net income¥460m2023-04-01 → 2024-03-31StandaloneProfit loss
Net income¥472m2022-04-01 → 2023-03-31StandaloneProfit loss
Net income¥1.0bn2021-04-01 → 2022-03-31dStandaloneNet income loss (5-year summary)
Net income¥791m2020-04-01 → 2021-03-31dStandaloneNet income loss (5-year summary)
Net income¥503m2019-04-01 → 2020-03-31dStandaloneNet income loss (5-year summary)
Total assets¥15.1bnat 2024-03-31StandaloneAssets
Total assets¥14.5bnat 2023-03-31StandaloneAssets
Total assets¥14.4bnat 2022-03-31dStandaloneTotal assets (5-year summary)
Total assets¥13.7bnat 2021-03-31dStandaloneTotal assets (5-year summary)
Total assets¥10.7bnat 2020-03-31dStandaloneTotal assets (5-year summary)
Total liabilities¥4.4bnat 2024-03-31StandaloneLiabilities
Total liabilities¥4.3bnat 2023-03-31StandaloneLiabilities
Net assets / equity¥10.6bnat 2024-03-31StandaloneNet assets
Net assets / equity¥10.2bnat 2023-03-31StandaloneNet assets
Net assets / equity¥9.8bnat 2022-03-31dStandaloneNet assets
Net assets / equity¥9.0bnat 2021-03-31dStandaloneNet assets (5-year summary)
Net assets / equity¥8.2bnat 2020-03-31dStandaloneNet assets (5-year summary)
Cash and deposits¥3.0bnat 2024-03-31StandaloneCash and deposits
Cash and deposits¥2.4bnat 2023-03-31StandaloneCash and deposits
EPS (basic)¥138.252023-04-01 → 2024-03-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥141.472022-04-01 → 2023-03-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥300.672021-04-01 → 2022-03-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥231.12020-04-01 → 2021-03-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥147.042019-04-01 → 2020-03-31dStandaloneBasic earnings loss per share (5-year summary)
Dividend per share¥232023-04-01 → 2024-03-31StandaloneDividend paid per share (5-year summary)
Dividend per share¥232022-04-01 → 2023-03-31StandaloneDividend paid per share (5-year summary)
Dividend per share¥232021-04-01 → 2022-03-31dStandaloneDividend paid per share (5-year summary)
Dividend per share¥232020-04-01 → 2021-03-31dStandaloneDividend paid per share (5-year summary)
Dividend per share¥102019-04-01 → 2020-03-31dStandaloneDividend paid per share (5-year summary)
Net assets per share¥3,194.85at 2024-03-31StandaloneNet assets per share (5-year summary)
Net assets per share¥3,066.27at 2023-03-31StandaloneNet assets per share (5-year summary)
Net assets per share¥2,934.15at 2022-03-31dStandaloneNet assets per share (5-year summary)
Net assets per share¥2,633.22at 2021-03-31dStandaloneNet assets per share (5-year summary)
Net assets per share¥2,398.25at 2020-03-31dStandaloneNet assets per share (5-year summary)
Equity ratio70.7%at 2024-03-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio70.5%at 2023-03-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio68.1%at 2022-03-31dStandaloneEquity to asset ratio (5-year summary)
Equity ratio66.0%at 2021-03-31dStandaloneEquity to asset ratio (5-year summary)
Equity ratio76.7%at 2020-03-31dStandaloneEquity to asset ratio (5-year summary)
ROE4.4%2023-04-01 → 2024-03-31StandaloneRate of return on equity (5-year summary)
ROE4.7%2022-04-01 → 2023-03-31StandaloneRate of return on equity (5-year summary)
ROE10.9%2021-04-01 → 2022-03-31dStandaloneRate of return on equity (5-year summary)
ROE9.2%2020-04-01 → 2021-03-31dStandaloneRate of return on equity (5-year summary)
ROE6.3%2019-04-01 → 2020-03-31dStandaloneRate of return on equity (5-year summary)
Shares issued4,216,000at 2024-03-31StandaloneTotal number of issued shares (5-year summary)
Shares issued4,216,000at 2023-03-31StandaloneTotal number of issued shares (5-year summary)
Shares issued4,216,000at 2022-03-31dStandaloneTotal number of issued shares (5-year summary)
Shares issued4,216,000at 2021-03-31dStandaloneTotal number of issued shares (5-year summary)
Shares issued4,216,000at 2020-03-31dStandaloneTotal number of issued shares (5-year summary)
Employees635at 2024-03-31StandaloneNumber of employees
Employees627at 2023-03-31StandaloneNumber of employees
Employees622at 2022-03-31dStandaloneNumber of employees
Employees775at 2021-03-31dStandaloneNumber of employees
Employees779at 2020-03-31dStandaloneNumber of employees

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 87
SegmentItemPeriodValue
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentscapex2023-04-01 → 2024-03-31¥4m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsdepreciation2023-04-01 → 2024-03-31¥2m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsemployeesat 2024-03-313 pure
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2023-04-01 → 2024-03-31¥131m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2023-04-01 → 2024-03-31¥126m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2023-04-01 → 2024-03-31¥6m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment assetsat 2024-03-31¥48m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2023-04-01 → 2024-03-31¥90m
Clinical Testing Businessreportable segmentcapex2023-04-01 → 2024-03-31¥124m
Clinical Testing Businessreportable segmentdepreciation2023-04-01 → 2024-03-31¥284m
Clinical Testing Businessreportable segmentemployeesat 2024-03-31539 pure
Clinical Testing Businessreportable segmentrevenue2023-04-01 → 2024-03-31¥7.6bn
Clinical Testing Businessreportable segmentrevenue external2023-04-01 → 2024-03-31¥7.6bn
Clinical Testing Businessreportable segmentsegment assetsat 2024-03-31¥3.5bn
Clinical Testing Businessreportable segmentsegment profit2023-04-01 → 2024-03-31¥109m
Dispensing Pharmacy Businessreportable segmentcapex2023-04-01 → 2024-03-31¥193m
Dispensing Pharmacy Businessreportable segmentdepreciation2023-04-01 → 2024-03-31¥109m
Dispensing Pharmacy Businessreportable segmentemployeesat 2024-03-31287 pure
Dispensing Pharmacy Businessreportable segmentrevenue2023-04-01 → 2024-03-31¥11.1bn
Dispensing Pharmacy Businessreportable segmentrevenue external2023-04-01 → 2024-03-31¥11.1bn
Dispensing Pharmacy Businessreportable segmentsegment assetsat 2024-03-31¥3.4bn
Dispensing Pharmacy Businessreportable segmentsegment profit2023-04-01 → 2024-03-31¥733m
Medical Devices Sales And Maintenance Businessreportable segmentcapex2023-04-01 → 2024-03-31¥25m
Medical Devices Sales And Maintenance Businessreportable segmentdepreciation2023-04-01 → 2024-03-31¥8m
Medical Devices Sales And Maintenance Businessreportable segmentemployeesat 2024-03-3121 pure
Medical Devices Sales And Maintenance Businessreportable segmentrevenue2023-04-01 → 2024-03-31¥1.6bn
Medical Devices Sales And Maintenance Businessreportable segmentrevenue external2023-04-01 → 2024-03-31¥937m
Medical Devices Sales And Maintenance Businessreportable segmentrevenue intersegment2023-04-01 → 2024-03-31¥626m
Medical Devices Sales And Maintenance Businessreportable segmentsegment assetsat 2024-03-31¥723m
Medical Devices Sales And Maintenance Businessreportable segmentsegment profit2023-04-01 → 2024-03-31−¥9m
—segment totalcapex2023-04-01 → 2024-03-31¥342m
—segment totaldepreciation2023-04-01 → 2024-03-31¥401m
—segment totalrevenue2023-04-01 → 2024-03-31¥20.2bn
—segment totalrevenue external2023-04-01 → 2024-03-31¥19.6bn
—segment totalrevenue intersegment2023-04-01 → 2024-03-31¥626m
—segment totalsegment assetsat 2024-03-31¥7.6bn
—segment totalsegment profit2023-04-01 → 2024-03-31¥834m
Total Of Reportable Segments And Otherssegment totalcapex2023-04-01 → 2024-03-31¥346m
Total Of Reportable Segments And Otherssegment totaldepreciation2023-04-01 → 2024-03-31¥403m
Total Of Reportable Segments And Otherssegment totalrevenue2023-04-01 → 2024-03-31¥20.3bn
Total Of Reportable Segments And Otherssegment totalrevenue external2023-04-01 → 2024-03-31¥19.7bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2023-04-01 → 2024-03-31¥632m
Total Of Reportable Segments And Otherssegment totalsegment assetsat 2024-03-31¥7.7bn
Total Of Reportable Segments And Otherssegment totalsegment profit2023-04-01 → 2024-03-31¥924m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentscapex2022-04-01 → 2023-03-31¥354,000
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsdepreciation2022-04-01 → 2023-03-31¥2m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2022-04-01 → 2023-03-31¥116m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2022-04-01 → 2023-03-31¥113m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2022-04-01 → 2023-03-31¥3m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment assetsat 2023-03-31¥44m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2022-04-01 → 2023-03-31¥75m
Clinical Testing Businessreportable segmentcapex2022-04-01 → 2023-03-31¥379m
Clinical Testing Businessreportable segmentdepreciation2022-04-01 → 2023-03-31¥250m
Clinical Testing Businessreportable segmentrevenue2022-04-01 → 2023-03-31¥8.3bn
Clinical Testing Businessreportable segmentrevenue external2022-04-01 → 2023-03-31¥8.3bn
Clinical Testing Businessreportable segmentsegment assetsat 2023-03-31¥4.0bn
Clinical Testing Businessreportable segmentsegment profit2022-04-01 → 2023-03-31¥564m
Dispensing Pharmacy Businessreportable segmentcapex2022-04-01 → 2023-03-31¥139m
Dispensing Pharmacy Businessreportable segmentdepreciation2022-04-01 → 2023-03-31¥120m
Dispensing Pharmacy Businessreportable segmentrevenue2022-04-01 → 2023-03-31¥10.7bn
Dispensing Pharmacy Businessreportable segmentrevenue external2022-04-01 → 2023-03-31¥10.7bn
Dispensing Pharmacy Businessreportable segmentsegment assetsat 2023-03-31¥3.3bn
Dispensing Pharmacy Businessreportable segmentsegment profit2022-04-01 → 2023-03-31¥821m
Medical Devices Sales And Maintenance Businessreportable segmentcapex2022-04-01 → 2023-03-31¥7m
Medical Devices Sales And Maintenance Businessreportable segmentdepreciation2022-04-01 → 2023-03-31¥8m
Medical Devices Sales And Maintenance Businessreportable segmentrevenue2022-04-01 → 2023-03-31¥1.7bn
Medical Devices Sales And Maintenance Businessreportable segmentrevenue external2022-04-01 → 2023-03-31¥1.0bn
Medical Devices Sales And Maintenance Businessreportable segmentrevenue intersegment2022-04-01 → 2023-03-31¥676m
Medical Devices Sales And Maintenance Businessreportable segmentsegment assetsat 2023-03-31¥745m
Medical Devices Sales And Maintenance Businessreportable segmentsegment profit2022-04-01 → 2023-03-31−¥5m
—segment totalcapex2022-04-01 → 2023-03-31¥525m
—segment totaldepreciation2022-04-01 → 2023-03-31¥378m
—segment totalrevenue2022-04-01 → 2023-03-31¥20.7bn
—segment totalrevenue external2022-04-01 → 2023-03-31¥20.0bn
—segment totalrevenue intersegment2022-04-01 → 2023-03-31¥676m
—segment totalsegment assetsat 2023-03-31¥8.0bn
—segment totalsegment profit2022-04-01 → 2023-03-31¥1.4bn
Total Of Reportable Segments And Otherssegment totalcapex2022-04-01 → 2023-03-31¥525m
Total Of Reportable Segments And Otherssegment totaldepreciation2022-04-01 → 2023-03-31¥379m
Total Of Reportable Segments And Otherssegment totalrevenue2022-04-01 → 2023-03-31¥20.8bn
Total Of Reportable Segments And Otherssegment totalrevenue external2022-04-01 → 2023-03-31¥20.1bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2022-04-01 → 2023-03-31¥679m
Total Of Reportable Segments And Otherssegment totalsegment assetsat 2023-03-31¥8.1bn
Total Of Reportable Segments And Otherssegment totalsegment profit2022-04-01 → 2023-03-31¥1.5bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsemployeesat 2024-03-313 pure
Clinical Testing Businessreportable segmentemployeesat 2024-03-31324 pure
Dispensing Pharmacy Businessreportable segmentemployeesat 2024-03-31287 pure

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 1,541
ItemContextValueUnit
Provision for directors retirement benefitsCurrentYearInstant_NonConsolidatedMember65553000JPY
Other nclPrior1YearInstant_NonConsolidatedMember16933000JPY
Other nclCurrentYearInstant_NonConsolidatedMember60403000JPY
Noncurrent liabilitiesPrior1YearInstant_NonConsolidatedMember1832913000JPY
Noncurrent liabilitiesCurrentYearInstant_NonConsolidatedMember1726851000JPY
LiabilitiesPrior1YearInstant_NonConsolidatedMember4274601000JPY
LiabilitiesCurrentYearInstant_NonConsolidatedMember4416686000JPY
Capital stockPrior1YearInstant_NonConsolidatedMember983350000JPY
Capital stockCurrentYearInstant_NonConsolidatedMember983350000JPY
Legal capital surplusPrior1YearInstant_NonConsolidatedMember1015270000JPY
Legal capital surplusCurrentYearInstant_NonConsolidatedMember1015270000JPY
Capital surplusPrior1YearInstant_NonConsolidatedMember1015270000JPY
Capital surplusCurrentYearInstant_NonConsolidatedMember1015270000JPY
Legal retained earningsPrior1YearInstant_NonConsolidatedMember74200000JPY
Legal retained earningsCurrentYearInstant_NonConsolidatedMember74200000JPY
General reservePrior1YearInstant_NonConsolidatedMember1690000000JPY
General reserveCurrentYearInstant_NonConsolidatedMember1690000000JPY
Reserve for advanced depreciation of noncurrent assetsPrior1YearInstant_NonConsolidatedMember11587000JPY
Reserve for advanced depreciation of noncurrent assetsCurrentYearInstant_NonConsolidatedMember14049000JPY
Retained earnings brought forwardPrior1YearInstant_NonConsolidatedMember7155715000JPY
Retained earnings brought forwardCurrentYearInstant_NonConsolidatedMember7537102000JPY
Retained earningsPrior1YearInstant_NonConsolidatedMember8931503000JPY
Retained earningsCurrentYearInstant_NonConsolidatedMember9315351000JPY
Treasury stockPrior1YearInstant_NonConsolidatedMember-758759000JPY
Treasury stockCurrentYearInstant_NonConsolidatedMember-758759000JPY
Shareholders equityPrior1YearInstant_NonConsolidatedMember10171363000JPY
Shareholders equityCurrentYearInstant_NonConsolidatedMember10555212000JPY
Valuation difference on available for sale securitiesPrior1YearInstant_NonConsolidatedMember41103000JPY
Valuation difference on available for sale securitiesCurrentYearInstant_NonConsolidatedMember85492000JPY
Valuation and translation adjustmentsPrior1YearInstant_NonConsolidatedMember41103000JPY
Valuation and translation adjustmentsCurrentYearInstant_NonConsolidatedMember85492000JPY
Net assetsPrior1YearInstant_NonConsolidatedMember10212467000JPY
Net assetsCurrentYearInstant_NonConsolidatedMember10640704000JPY
Liabilities and net assetsPrior1YearInstant_NonConsolidatedMember14487068000JPY
Liabilities and net assetsCurrentYearInstant_NonConsolidatedMember15057391000JPY
Net salesPrior1YearDuration_NonConsolidatedMember17613669000JPY
Net salesCurrentYearDuration_NonConsolidatedMember17333697000JPY
Cost of salesPrior1YearDuration_NonConsolidatedMember12135961000JPY
Cost of salesCurrentYearDuration_NonConsolidatedMember12193745000JPY
Gross profitPrior1YearDuration_NonConsolidatedMember5477707000JPY
Gross profitCurrentYearDuration_NonConsolidatedMember5139952000JPY
Selling general and administrative expensesPrior1YearDuration_NonConsolidatedMember4772650000JPY
Selling general and administrative expensesCurrentYearDuration_NonConsolidatedMember4771425000JPY
Operating incomePrior1YearDuration_NonConsolidatedMember705057000JPY
Operating incomeCurrentYearDuration_NonConsolidatedMember368526000JPY
Interest income noiPrior1YearDuration_NonConsolidatedMember103000JPY
Interest income noiCurrentYearDuration_NonConsolidatedMember63000JPY
Dividends income noiPrior1YearDuration_NonConsolidatedMember50147000JPY
Dividends income noiCurrentYearDuration_NonConsolidatedMember86020000JPY
Fiduciary obligation fee noiPrior1YearDuration_NonConsolidatedMember107343000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 24 of 24 passed
balance sheet identityconsolidated 2023-03-31pass rounding
balance sheet identityconsolidated 2024-03-31pass rounding
balance sheet identitynon_consolidated 2023-03-31pass
balance sheet identitynon_consolidated 2024-03-31pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2022-03-31pass
statement vs summary · net assetsconsolidated 2023-03-31pass
statement vs summary · net assetsconsolidated 2024-03-31pass
statement vs summary · net assetsnon_consolidated 2022-03-31pass
statement vs summary · net assetsnon_consolidated 2023-03-31pass
statement vs summary · net assetsnon_consolidated 2024-03-31pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2023-03-31pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2024-03-31pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2023-03-31pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2024-03-31pass
statement vs summary · revenueconsolidated 2022-04-01/2023-03-31pass
statement vs summary · revenueconsolidated 2023-04-01/2024-03-31pass
statement vs summary · revenuenon_consolidated 2022-04-01/2023-03-31pass
statement vs summary · revenuenon_consolidated 2023-04-01/2024-03-31pass
statement vs summary · total assetsconsolidated 2023-03-31pass
statement vs summary · total assetsconsolidated 2024-03-31pass
statement vs summary · total assetsnon_consolidated 2023-03-31pass
statement vs summary · total assetsnon_consolidated 2024-03-31pass